

Date: 14.11.2022

To,

Department of Corporate Services Bombay Stock Exchange Limited Floor 25, PJ Towers Dalal Street, Mumbai – 400 001	National Stock Exchange of India Ltd Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai 400 051
---	--

Dear Sir,

Sub: Outcome of the Board Meeting held on 14.11.2022

Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) 2015, this is to inform you that the Board of Directors in their just concluded Board meeting held today have:

1. Considered and adopted the Un-audited financial results of the Company for the quarter / three months ended 30.06.2022;
2. Considered and adopted the Un-audited financial results of the Company for the quarter / half year ended 30.09.2022;

In this connection find attached the following:

1. Copy of Un-audited financial results of the Company for the quarter / three months ended 30.06.2022 alongwith Limited Review Report
2. Copy of Un-audited financial results of the Company for the quarter / half year ended 30.09.2022 alongwith Limited Review Report

The meeting commenced at 4.00 PM and ended at 5:15 PM.

This is for your information and records.

Thanking you
Yours truly

For Celestial Biolabs Limited

NAGA
LATHA
SADA

Digitally signed
by NAGA LATHA
SADA
Date: 2022.11.14
17:16:24 +05'30'

Sada Naga Latha
Compliance officer & Company Secretary
M No. ACS 59897

CELESTIAL BIOLABS LIMITED
Plot No.82, Venkat Reddy Nagar, Narapally, Medchal, Malkajgiri Dist Hyderabad - 500039
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2022

SL.NO.	PARTICULARS	Rs in lacs			
		Quarter Ended		Year Ended	
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
I	a) Revenue from operations	5.51	6.31	-	14.75
II	b) Other Income	-	-	-	-
III	Total Income (I+II)	5.51	6.31	-	14.75
IV	Expenditure				
	a) Cost of raw and packing materials consumed	3.36	3.90	-	8.92
	b) Purchase of Traded Products	-	-	-	-
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-
	d) Employee Benefits Expense	4.18	4.24	1.80	12.32
	e) Depreciation and amortization	0.70	0.70	0.83	3.02
	f) Finance Cost	0.08	-	-	0.07
	g) Other Expenses	7.33	24.99	2.90	31.36
	Total expenses	15.65	33.83	5.53	55.70
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(10.15)	(27.52)	(5.53)	(40.95)
VI	Exceptional items	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(10.15)	(27.52)	(5.53)	(40.95)
VIII	Tax expense	-	-	-	-
IX	Net Profit / (Loss) for the period (VII-VIII)	(10.15)	(27.52)	(5.53)	(40.95)
X	Other Comprehensive Income,	-	-	-	-
	Total Other Comprehensive Income, net of Tax	-	-	-	-
XI	Total Comprehensive Income for the period	(10.15)	(27.52)	(5.53)	(40.95)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period				
	Basic	(0.04)	(0.12)	(0.02)	(0.18)
	Diluted	(0.04)	(0.12)	(0.02)	(0.18)

Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.11.2022
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 30th June, 2022 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
- During the Financial year 2019-20 the company incurred net losses of Rs. 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 lakhs at the beginning of the financial year 2019-20 came down to Rs. 393.13 lakhs for year ended 31.3.2020. Also there are no sales during the financial year 2020-21 and sales in the financial year 2021-22 amounts to Rs. 14.75 lakhs. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation

HYDERABAD
Date: 14.11.2022


Managing Director





LIMITED REVIEW REPORT

To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited financial results of M/s Celestial Biolabs Limited for quarter ended 30 June, 2022" ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

We draw attention to Note 4 to financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 4 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

Our conclusion is not modified in respect of this matter

For M Surendra and Associates
Chartered Accountants
Firm Reg No. 017280S



P. Shaik Shavali P

CA Shaik Shavali P
Partner
M.No. 245517

Place : Hyderabad
Date: 14.11.2022

UDIN: 22245517BDAKELQ2041



LIMITED REVIEW REPORT

To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited financial results of M/s Celestial Biolabs Limited for quarter ended 30 September, 2022", and year to date results for the period from 01 April 2022 to 30 September 2022 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial Results, prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

We draw attention to Note 4 to the Statement, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 4 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

Our conclusion is not modified in respect of this matter

Place : Hyderabad
Date: 14.11.2022

For M Surendra and Associates
Chartered Accountants
Firm Reg No. 017280S

P. Shaik Shavali P

CA Shaik Shavali P
Partner
M.No. 245517



UDIN: 22245517BDBPTR2673,

BALANCE SHEET		
Particulars	September 30, 2022	March 31, 2022
ASSETS		
Non- current assets		
(a) Property, Plant & Equipment	9.39	10.16
(b) Capital work - in - progress	1,281.58	1,281.58
	1,290.96	1,291.74
Current Assets		
(a) Inventories	4.07	4.88
(b) Financial Assets		
(i) Trade receivables	374.78	383.28
(ii) Cash and cash equivalents	1.29	0.13
(iii) Other financial asset		-
(c) Current Tax Assets (Net)	42.80	37.74
(d) Other Current Assets	422.93	426.03
TOTAL	1,713.90	1,717.77
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity share capital	2,258.63	2,258.63
(b) Other Equity	-1,941.94	-1,923.59
Total equity	316.69	335.04
LIABILITIES		
Non- current liabilities		
(a) Financial Liabilities		
(i). Borrowings	860.98	848.74
(ii). Trade Payables		
(b) Deferred tax liabilities (Net)		
	860.98	848.74
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	305.33	305.33
(ii) Trade payables		
(a) Dues of micro enterprise and small enterprises		
(b) Dues of creditors other than, micro enterprises and small enterprises	23.78	26.01
(iii) Other financial liabilities	25.00	25.00
b) Other current liabilities	182.12	177.63
c) Provisins		-
Income Tax liabilities(net)		
	536.23	533.98
TOTAL	1,713.90	1,717.77
Significant Accounting Policies		
Notes to the Financial Statements	-0.00	-0.00

HYDERABAD
Date: 14.11.2022


Managing Director



CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th Sep, 2022

SL.NO.	PARTICULARS	Rs In lacs					
		Quarter ended			Six month period ended		Year Ended
		30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Unaudited)	30.09.2022 (Unaudited)	30.09.2021 (Unaudited)	31.03.2022 (Audited)
I	a) Revenue from operations	4.18	5.51	4.82	9.69	4.82	14.75
II	b) Other Income	-	-	-	-	-	-
III	Total income (I+II)	4.18	5.51	4.82	9.69	4.82	14.75
IV	Expenditure						
	a) Cost of raw and packing materials consumed	2.51	3.36	2.58	5.87	2.58	8.92
	b) Purchase of Traded Products	-	-	-	-	-	-
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-	-	-
	d) Employee Benefits Expense	4.53	4.18	2.55	8.70	4.35	12.32
	e) Depreciation and amortization	0.70	0.70	0.78	1.41	1.61	3.02
	f) Finance Cost	0.07	0.08	-	0.16	-	0.07
	g) Other Expenses	4.56	7.33	2.00	11.89	4.90	31.36
	Total expenses	12.38	15.66	7.90	28.03	13.43	55.70
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(8.20)	(10.15)	(3.08)	(18.35)	(8.61)	(40.95)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(8.20)	(10.15)	(3.08)	(18.35)	(8.61)	(40.95)
VIII	Tax expense	-	-	-	-	-	-
IX	Net Profit / (Loss) for the period (VII-VIII)	(8.20)	(10.15)	(3.08)	(18.35)	(8.61)	(40.95)
X	Other Comprehensive Income,	-	-	-	-	-	-
	Total Other Comprehensive Income, net of Tax	-	-	-	-	-	-
XI	Total Comprehensive Income for the period	(8.20)	(10.15)	(3.08)	(18.35)	(8.61)	(40.95)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period						
	Basic	(0.04)	(0.04)	(0.01)	(0.08)	(0.04)	(0.18)
	Diluted	(0.04)	(0.04)	(0.01)	(0.08)	(0.04)	(0.18)

Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.11.2022
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 30th September, 2022 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
- During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 lakhs at the beginning of the financial year 2019-20 came down to Rs. 393.13 lakhs for year ended 31.3.2020. Also there are no sales during the financial year 2020-21 and sales in the financial year 2021-22 amounts to Rs 14.75 lakhs. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation

HYDERABAD
Date: 14.11.2022


Managing Director



CELESTIAL BIOLABS LIMITED

Cash Flow Statement For the Quarter ended 30th September, 2022

Particulars	Six months ended Sep 30, 2022	Six months ended Sep 30, 2021	year ended ended 31.03.2022
A. Cash Flow From Operating Activities			
Net Profit before Tax & Appropriations	(18.35)	(8.62)	(40.95)
Depreciation & Amortisation of Intangible assets	1.41	1.61	3.02
Operating Profit Before Working Capital Charges	(16.94)	(7.01)	(37.93)
Adjustments for:			
(Increase)/Decrease in Inventory	0.81	(0.46)	0.33
(Increase)/Decrease in Trade Receivables	8.49	(4.76)	(5.26)
(Increase)/Decrease in Other Current Assets	(5.06)	-	-
(Increase)/Decrease in Trade Payable	(2.24)	(2.14)	(11.89)
(Increase)/Decrease in Other financial liabilities		-	25.00
(Increase)/Decrease in Other Current Liabilities	4.49	(0.40)	2.23
(Increase)/Decrease in Provisions		-	-
Cash Generated from Operations	(10.44)	(14.77)	(27.52)
Net Cash generated from Operating Activities (A)	(10.44)	(14.77)	(27.52)
B. Cash Flow from Investing Activities:			
Purchases of fixed assets			(0.38)
Sale of Land and Building	(0.64)	(0.01)	-
Capital work in progress		-	-
Other intangible assets		-	-
Intangible assets under development		-	-
Net Cash generated from/(Used) Investing Activities (B)	(0.64)	(0.01)	(0.38)
C. Cash Flow from Financial Activities			
Net Cash generated from/(used) Financial Activities (c)			
Increase/(Decrease) in Borrowings	12.23	12.82	25.90
Interest and Financial Charges Paid		-	-
	12.23	12.82	25.90
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	1.16	(1.96)	(2.00)
Cash and Cash equivalents at the beginning of the year	0.13	2.13	2.13
Cash and Cash equivalents (Closing Balance)	1.29	0.17	0.13

HYDERABAD
Date: 14.11.2022


Managing Director

